Refining endpoints in brain tumor clinical trials

被引：38

作者：

Meyers, Christina A. ^{[1
]}

Rock, Edwin P. ^{[2
]}

Fine, Howard A. ^{[3
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA

[2] Otsuka Pharmaceut Dev & Commercializat Inc, Rockville, MD USA

[3] NCI, Neurooncol Branch, Bethesda, MD 20892 USA

来源：

JOURNAL OF NEURO-ONCOLOGY | 2012年 / 108卷 / 02期

关键词：

Brain cancer; Clinical trials; Neurocognitive function; NEUROCOGNITIVE FUNCTION; COGNITIVE FUNCTION; PROGRESSION; RADIATION; CANCER; GLIOMA;

D O I：

10.1007/s11060-012-0813-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

As targeted therapies advance treatment for brain tumors, standard clinical trial endpoints of survival, progression free survival and radiographic response have become insufficient to capture clinical benefit. Brain cancer is a malignancy with neurodegenerative features. In this setting prolongation of life and/or radiographic stability are less clinically meaningful if neurocognitive function substantially declines. Hence evaluation of new therapeutic strategies should routinely include periodic assessment of neurocognitive function.

引用

页码：227 / 230

页数：4

共 50 条

[21] Are better endpoints and better design of clinical trials needed? [J].

Fransen, J ;

van Riel, PLCM .

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2004, 18 (01) :97-109

[22] Interpretation of clinical endpoints in trials of acute myeloid leukemia [J].

Medeiros, Bruno C. .

LEUKEMIA RESEARCH, 2018, 68 :32-39

[23] Novel Procedures for Validating Surrogate Endpoints in Clinical Trials [J].

Cleophas, Ton J. ;

Zwinderman, Aeilko H. ;

Chaib, Amel H. .

CURRENT CLINICAL PHARMACOLOGY, 2007, 2 (02) :123-128

[24] Imaging endpoints for clinical trials in MacTel type 2 [J].

Pauleikhoff, Daniel ;

Pauleikhoff, Laurenz ;

Chew, Emily Y. .

EYE, 2022, 36 (02) :284-293

[25] Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease [J].

Elghanam, Yomna ;

Purja, Sujata ;

Kim, Eun Young .

JOURNAL OF ALZHEIMERS DISEASE, 2024, 99 (02) :693-703

[26] Endpoints in clinical trials: does evidence only originate from 'hard' or mortality endpoints? [J].

Asmar, Roland ;

Hosseini, Hassan .

JOURNAL OF HYPERTENSION, 2009, 27 :S45-S50

[27] Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials [J].

Ellingson, Benjamin M. ;

Bendszus, Martin ;

Boxerman, Jerrold ;

Barboriak, Daniel ;

Erickson, Bradley J. ;

Smits, Marion ;

Nelson, Sarah J. ;

Gerstner, Elizabeth ;

Alexander, Brian ;

Goldmacher, Gregory ;

Wick, Wolfgang ;

Vogelbaum, Michael ;

Weller, Michael ;

Galanis, Evanthia ;

Kalpathy-Cramer, Jayashree ;

Shankar, Lalitha ;

Jacobs, Paula ;

Pope, Whitney B. ;

Yang, Dewen ;

Chung, Caroline ;

Knopp, Michael V. ;

Cha, Soonme ;

van den Bent, Martin J. ;

Chang, Susan ;

Al Yung, W. K. ;

Cloughesy, Timothy F. ;

Wen, Patrick Y. ;

Gilbert, Mark R. .

NEURO-ONCOLOGY, 2015, 17 (09) :1188-1198

[28] Identifying cut points for biomarker defined subset effects in clinical trials with survival endpoints [J].

He, Pei .

CONTEMPORARY CLINICAL TRIALS, 2014, 38 (02) :333-337

[29] Estimating and testing treatment effects on two binary endpoints and association between endpoints in clinical trials [J].

Wang, WQ ;

Woolson, RF ;

Clarke, WR .

COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION, 2005, 34 (03) :751-769

[30] The Ongoing Evolution of Optimal Clinical Endpoints for Heart Failure Trials [J].

Krum, Henry ;

Hopper, Ingrid .

JACC-HEART FAILURE, 2015, 3 (08) :615-617

← 1 2 3 4 5 →